Stockscreener 앱 받기
7.19
7.70%
-0.60
시간 외 거래:
7.33
0.14
+1.95%
전일 마감가:
$7.79
열려 있는:
$7.45
하루 거래량:
1.66M
Relative Volume:
1.33
시가총액:
$292.18M
수익:
$128.29M
순이익/손실:
$-30.69M
주가수익비율:
-8.7683
EPS:
-0.82
순현금흐름:
$-27.17M
1주 성능:
-7.82%
1개월 성능:
-43.78%
6개월 성능:
-78.24%
1년 성능:
-85.43%
1일 변동 폭
$6.699
$7.54
1주일 범위
$6.699
$7.99
52주 변동 폭
$6.32
$58.23
Rxsight Inc Stock (RXST) Company Profile
명칭
Rxsight Inc
전화
949-521-7822
주소
100 COLUMBIA STREET, ALISO VIEJO
RXST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.19 | 306.81M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-07-09 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-09 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 개시 | Piper Sandler | Neutral |
| 2025-04-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-04-04 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2025-04-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-10-29 | 개시 | Jefferies | Buy |
| 2024-08-20 | 재확인 | Needham | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-05-07 | 재확인 | BTIG Research | Buy |
| 2023-12-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 개시 | Morgan Stanley | Overweight |
| 2023-04-13 | 개시 | Oppenheimer | Outperform |
| 2022-12-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 개시 | Needham | Buy |
모두보기
Rxsight Inc 주식(RXST)의 최신 뉴스
RXST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that RxSight, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is RxSight Inc. building a consolidation baseFree Buy Low Sell High Stock Watch - Newser
Should you hold or exit RxSight Inc. nowStable Swing Setup with Safety Analysis - Newser
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
RXST Investors Have Opportunity To Lead RxSight, Inc. Securities Fraud Lawsuit - Barchart.com
Faruqi & Faruqi Reminds RxSight Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025RXST - PR Newswire
RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - GlobeNewswire Inc.
Automated trading signals detected on RxSight Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
RxSight's Strategic Reinvention: Can International Expansion and Product Innovation Justify a Re-Rating? - AInvest
Class Action Filed Against RxSight, Inc. (RXST) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Investors in RxSight, Inc. (RXST): Protect Your RightsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages RxSight, Inc. - GlobeNewswire
UBS Adjusts RxSight Price Target to $8 From $16, Maintains Neutral Rating - MarketScreener
RxSight stock price target cut by UBS to $8 on weak LDD placements - Investing.com
RxSight Inc. (RXST) PT Lowered to $8 at UBS - StreetInsider
Earnings call transcript: Rxsight Q2 2025 reports wider loss, stock rises - Investing.com
RxSight, Inc. Reports Q2 2025 Financial Results - TipRanks
RxSight’s Revenue Slips As Losses Grow But Margins Hold Steady - Finimize
RxSight, Inc. Presents Second Quarter 2025 Revenue, Reiterates Full-Year Guidance - VisionMonday.com
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Rxsight earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
RxSight, Inc. (RXST) Misses Q2 EPS by 10c, provides guidance - StreetInsider
Investors in RxSight, Inc. Should Contact The Gross Law - GlobeNewswire
RxSight, Inc. Reports Second Quarter 2025 Financial Results - The Manila Times
RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before September 22, 2025RxSight, Inc. (RXST) - ACCESS Newswire
Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39% - simplywall.st
RxSight, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationRXST - PR Newswire
RXST SHAREHOLDERS: RxSight, Inc. Stock Drop Triggers - GlobeNewswire
Join Class Action to Recover Losses from RxSight, Inc. (RXST)Contact Levi & Korsinsky Before September 22, 2025 - TradingView
RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lost Money on RxSight, Inc. (RXST)? Join Class Action Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Technical signs of recovery in RxSight Inc.Conservative Equity Setup with Signal Analysis - Newser
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that RxSight, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RxSight Expands Board with New Director Appointment - The Globe and Mail
Levi & Korsinsky Notifies RxSight, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – RXST - GlobeNewswire
RxSight, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in RxSight, Inc. LawsuitRXST - PR Newswire
RXST CLASS ACTION: RxSight, Inc. Investors that Lost Money - GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages RxSight, - GlobeNewswire
Using R and stats models for RxSight Inc. forecastingTrade Flow Monitor with Volume Tracker - Newser
RXST LEGAL NOTICE: BFA Law Reminds RxSight, Inc. Investors with Losses of the Imminent September 22 Securities Class Action Deadline - Newsfile
RXSIGHT, INC. (NASDAQ: RXST) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Shareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22nd - PR Newswire
Class Action Filed Against RxSight, Inc. (RXST)September 22, 2025 Deadline to Join – Contact The Gross Law Firm - GlobeNewswire
RxSight (RXST) adds ex-Axonics CEO Raymond Cohen to Board | RXST SEC FilingForm 8-K - Stock Titan
RxSight (RXST) adds ex-Axonics CEO Raymond Cohen to Board | GBCI SEC FilingForm S-8 - Stock Titan
Shareholders who lost money on their RxSight, Inc. (NASDAQ: - GlobeNewswire
Rxsight Inc (RXST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
자본화:
|
볼륨(24시간):